Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of February 2024, with a report date of February 26, 2024. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W2044.
- Transaction Price: $42.160 per ADS.
- Transaction Volume: Total of 2,824.8551 ADSs acquired across three transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely details routine acquisitions of ADSs by executives via dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific transactions executed on February 22, 2024, on the New York Stock Exchange (XNYS).
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from the reinvestment of dividends, not open-market purchases.
- Executives Involved:
- Dr. Hal Barron (Non-Executive Director): Acquired 2,773.2519 ADSs via the Executive Supplemental Savings Plan and 70 ADSs via the 401(k) plan.
- James Ford (SVP and Group General Counsel): Acquired 51.6032 ADSs via the Executive Supplemental Savings Plan.
- Market Price: The transactions occurred at a uniform price of $42.160 per ADS.
- Financial Data Limitation: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for performance metrics.